GE Healthcare announced today that it will install India’s first FlexFactory™ in Hyderabad at Dr. Reddy’s Laboratories’ biologics production facility.

With this expansion, Dr. Reddy’s will be able to increase its manufacturing capacity for its portfolio of biosimilars within 9­­ to 12 months. Most significantly, the new FlexFactory will allow the facility to make the transition from stainless-steel to single-use technologies, with an estimated change-over-time reduction of 50%.

“We are delighted to be working with GE Healthcare to expand our biologics manufacturing footprint. We strongly believe that the FlexFactory platform from GE will enable us to rapidly ramp up capacity and serve more patients in both emerging markets and highly regulated markets,” said Cartikeya Reddy, Ph.D., head of biologics at Dr. Reddy’s.

“We are pleased to partner with Dr. Reddy’s in their efforts to increase the availability and affordability of biopharmaceuticals globally by bringing single-use, flexible manufacturing capacity to its facility in Hyderabad,” remarked Milind Palsule, country manager, South Asia, GE Healthcare Life Sciences. “India today has one of the fastest growing biopharma sectors in the world and we are keen to support this development and the production capability of Indian pharma players with the latest biopharma technology and know-how.”

For more articles like this read our Insights column from the June 15, 2017 issue of GEN.

Previous articleNovelogics, CDRD Partner on Antibody Tech Targeting Cancer Decoy Proteins
Next articlePharmaMar Licenses Rights to Cancer Candidate for Southeast Asia, Australia